Fengkui Zhang
The Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) · Hematology Hospital, Chinese Academy of Medical Sciences · Hematology Hospital of the Chinese Academy of Medical Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fengkui Zhang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:17 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07256301 · A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)Shanghai Lanyi Therapeutics Co., Ltd. · recruiting · PNH - Paroxysmal Nocturnal Hemoglobinuria · principal investigator
- Ph1/Ph2NCT06818838 · A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher DiseaseLingyi Biotech Co., Ltd. · recruiting · Gaucher Disease Type 1 · principal investigator
- Ph2NCT06764303 · A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria PatientsNanjing Chia-tai Tianqing Pharmaceutical · active not recruiting · Paroxysmal Nocturnal Hemoglobinuria · principal investigator
- Ph2NCT06050226 · A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Wuhan Createrna Science and Technology Co., Ltd · completed · Paroxysmal Nocturnal Hemoglobinuria · principal investigator
- Ph2/Ph3NCT05535933 · HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaHutchmed · active not recruiting · Warm Antibody Autoimmune Hemolytic Anemia · principal investigator
- Ph2NCT01503502 · A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaJiangsu HengRui Medicine Co., Ltd. · unknown · Myelogenous Leukemia, Chronic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:17 UTC. The ranking covers the 200 most relevant of 810 PubMed records, and a shared surname and initials can bring in a namesake. All 810 on PubMed
- 1,719 citationsRCR 75.1
- 800 citationsRCR 30.6
- A Controlled Trial of Erenumab for Episodic Migraine.N Engl J Med · 2017646 citationsRCR 26.1
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.N Engl J Med · 2021373 citationsRCR 26.9
- A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.Ann Rheum Dis · 2018262 citationsRCR 11.2
- 213 citationsRCR 19.7
- 198 citationsRCR 9.5
- 157 citationsRCR 14.0
- Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.Ann Rheum Dis · 2024142 citationsRCR 21.2
- Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.Nat Med · 2024130 citationsRCR 16.1